2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
21
Plasma cell
3
Gastrointestinal
3
Tumor-Agnostic
2
Thoracic
2
Gynecologic
2
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
CNS
1
Breast
1
Conditions
Venous Thromboembolism
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Docetaxel
409
pembrolizumab
332
Prednisone
290
enzalutamide
285
Gemcitabine
274
Radiotherapy
270
Magnetic Resonance Spectroscopy
269
Nivolumab
253
Abiraterone Acetate
218
Cisplatin
212
Leuprolide
195
Radiosurgery
192
Sunitinib
188
Carboplatin
161
Androgen Antagonists
156
bicalutamide
152
Specimen Handling
149
Goserelin
149
Ipilimumab
131
Paclitaxel
126
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
122
apalutamide
118
Cyclophosphamide
117
Bevacizumab
116
Sorafenib
114
Everolimus
111
abiraterone
108
cabozantinib
105
atezolizumab
105
Biopsy
101
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Rivaroxaban
×
Genitourinary
×
Clear all
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled